Form 13-F position report

TRISALUS LIFE SCIENCES INC

Reported by MORGAN STANLEY

TLSI CUSIP 89680M101 Manager CIK 0000895421

Reported 1,135 shares, down 837 (42.4%) from the prior quarter.

Reported value -51.9%; share count -42.4% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q3 2024
Shares 1,135 Quarter-end amount reported
Reported value $5,232 Fair value at quarter end
Consecutive quarters held 5 Through Q3 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-09-30 5821
2023-12-31 105532
2024-03-31 129763
2024-06-30 10885
2024-09-30 5232
2024-12-31 0
2025-03-31 13033
2025-06-30 306987
2025-09-30 83593
2025-12-31 2549481
2026-03-31 1575636
2026-06-30 1828255

Quarterly position history

How this manager's reported quarter-end position changed over time.

12 quarters
Quarterly reported position history for TRISALUS LIFE SCIENCES INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Added 401,814 +7,905 (2.0%) < 0.01% $1,828,255 2026-08-13
Q1 2026 Added 393,909 +28,654 (7.8%) < 0.01% $1,575,636 2026-05-15
Q4 2025 Added 365,255 +347,278 (1931.8%) < 0.01% $2,549,481 2026-02-13
Q3 2025 Reduced 17,977 -38,351 (-68.1%) < 0.01% $83,593 2025-11-14
Q2 2025 Added 56,328 +53,967 (2285.8%) < 0.01% $306,987 2025-08-15
Q1 2025 New 2,361 +2,361 (0.0%) < 0.01% $13,033 2025-05-15
Q4 2024 Reduced 0 -1,135 (-100.0%) 0 $0 2025-02-14
Q3 2024 Reduced 1,135 -837 (-42.4%) < 0.01% $5,232 2024-11-14
Q2 2024 Reduced 1,972 -11,337 (-85.2%) < 0.01% $10,885 2024-08-14
Q1 2024 Added 13,309 +820 (6.6%) < 0.01% $129,763 2024-05-15
Q4 2023 Added 12,489 +11,352 (998.4%) < 0.01% $105,532 2024-02-13
Q3 2023 New 1,137 +1,137 (0.0%) < 0.01% $5,821 2023-11-15

Who else reported the position

38 managers reported TRISALUS LIFE SCIENCES INC for Q3 2024.

Managers reporting TRISALUS LIFE SCIENCES INC in Q3 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Wealthcare Advisory Partners LLC New 643,740 +643,740 0.08% $2,967,641 1 qtr
Duquesne Family Office LLC Unchanged 426,921 0 0.07% $1,968,000 3 qtrs
VANGUARD GROUP INC Unchanged 416,138 0 < 0.01% $1,918,396 4 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 200,427 +62,542 < 0.01% $924,191 5 qtrs
MILLENNIUM MANAGEMENT LLC Reduced 97,888 -25,016 < 0.01% $451,264 3 qtrs
MSD Partners L P New 39,999 +39,999 0.12% $184,395 1 qtr
Exos Asset Management LLC Reduced 38,604 -129,006 17.27% $177,964 2 qtrs
Lido Advisors LLC Reduced 35,024 -9,383 < 0.01% $161,461 2 qtrs
Connecticut Wealth Management LLC Unchanged 32,879 0 < 0.01% $151,572 5 qtrs
BlackRock Inc New 30,270 +30,270 < 0.01% $139,545 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2024
Filed
November 14, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
0
None
1,135

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.